NDA (New Drug Application)
ANDA (Generic Application)
Track protection status across key markets to assess launch feasibility.
It is formulated by 2 pharmaceutical companies such as BAUSCH, TARO. It is marketed under 2 brand names, including DUOBRII, HALOBETASOL PROPIONATE AND TAZAROTENE. Available in 1 different strength, such as 0.01%;0.045%, and administered through 1 route including LOTION;TOPICAL.
API availability: Loading API feasibility...
Licensing: 2 potential partnersUS Launch window: Loading launch window...
Stay ahead with worldwide patent expiry and latest updates.
FDA approval history for this ingredient
Stay ahead with worldwide patent expiry insights, exclusivity data, and latest updates.
Key expiration dates for US patents covering this ingredient
Stay ahead with worldwide patent expiry insights, market data, and research updates.
Latest drug strengths approved by FDA
| Strength | Route of Administration | Companies | Latest Approval Date |
|---|
Patents approved by the FDA for the ingredient
|
|
Patent Number | Publication Date | Legal Status | Patent Expiry Date | |
|---|---|---|---|---|---|
| {"application_id":"63485","ingredient":"HALOBETASOL PROPIONATE; TAZAROTENE","trade_name":"DUOBRII","family_id":"ca65ddf7d8bc40138e4c","publication_number":"US8809307B2","cleaned_patent_number":"8809307","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2031-11-02","publication_date":"2014-08-19","legal_status":"Granted"} | US8809307B2 Formulation | 19 Aug, 2014 | Granted | 02 Nov, 2031 | |
| {"application_id":"120713","ingredient":"HALOBETASOL PROPIONATE; TAZAROTENE","trade_name":"DUOBRII","family_id":"ca65ddf7d8bc40138e4c","publication_number":"US11839656B2","cleaned_patent_number":"11839656","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2031-11-02","publication_date":"2023-12-12","legal_status":"Granted"} | US11839656B2 | 12 Dec, 2023 | Granted | 02 Nov, 2031 | |
| {"application_id":"63487","ingredient":"HALOBETASOL PROPIONATE; TAZAROTENE","trade_name":"DUOBRII","family_id":"ca65ddf7d8bc40138e4c","publication_number":"US11957753B2","cleaned_patent_number":"11957753","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2031-11-02","publication_date":"2024-04-16","legal_status":"Granted"} | US11957753B2 Formulation | 16 Apr, 2024 | Granted | 02 Nov, 2031 | |
| {"application_id":"63488","ingredient":"HALOBETASOL PROPIONATE; TAZAROTENE","trade_name":"DUOBRII","family_id":"ca65ddf7d8bc40138e4c","publication_number":"US11986527B2","cleaned_patent_number":"11986527","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2031-11-02","publication_date":"2024-05-21","legal_status":"Granted"} | US11986527B2 | 21 May, 2024 | Granted | 02 Nov, 2031 | |
| {"application_id":"130699","ingredient":"HALOBETASOL PROPIONATE; TAZAROTENE","trade_name":"DUOBRII","family_id":"ca65ddf7d8bc40138e4c","publication_number":"US12076403B2","cleaned_patent_number":"12076403","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2031-11-02","publication_date":"2024-09-03","legal_status":"Granted"} | US12076403B2 Formulation | 03 Sep, 2024 | Granted | 02 Nov, 2031 | |
| {"application_id":"63471","ingredient":"HALOBETASOL PROPIONATE; TAZAROTENE","trade_name":"DUOBRII","family_id":"ca65ddf7d8bc40138e4c","publication_number":"US10478502B2","cleaned_patent_number":"10478502","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2031-11-02","publication_date":"2019-11-19","legal_status":"Granted"} | US10478502B2 Formulation | 19 Nov, 2019 | Granted | 02 Nov, 2031 | |
| {"application_id":"63460","ingredient":"HALOBETASOL PROPIONATE; TAZAROTENE","trade_name":"DUOBRII","family_id":"badff805276d455188d6","publication_number":"US10426787B2","cleaned_patent_number":"10426787","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2036-06-06","publication_date":"2019-10-01","legal_status":"Granted"} | US10426787B2 | 01 Oct, 2019 | Granted | 06 Jun, 2036 | |
| {"application_id":"63459","ingredient":"HALOBETASOL PROPIONATE; TAZAROTENE","trade_name":"DUOBRII","family_id":"badff805276d455188d6","publication_number":"US10251895B2","cleaned_patent_number":"10251895","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2036-06-06","publication_date":"2019-04-09","legal_status":"Granted"} | US10251895B2 Formulation | 09 Apr, 2019 | Granted | 06 Jun, 2036 | |
| {"application_id":"115248","ingredient":"HALOBETASOL PROPIONATE; TAZAROTENE","trade_name":"DUOBRII","family_id":"d558c5d165364dd98b7c","publication_number":"US11648256B2","cleaned_patent_number":"11648256","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2036-06-06","publication_date":"2023-05-16","legal_status":"Granted"} | US11648256B2 Formulation | 16 May, 2023 | Granted | 06 Jun, 2036 | |
| {"application_id":"63464","ingredient":"HALOBETASOL PROPIONATE; TAZAROTENE","trade_name":"DUOBRII","family_id":"d558c5d165364dd98b7c","publication_number":"US11679115B2","cleaned_patent_number":"11679115","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2036-06-06","publication_date":"2023-06-20","legal_status":"Granted"} | US11679115B2 Formulation | 20 Jun, 2023 | Granted | 06 Jun, 2036 |
Latest clinical trials and research studies for this ingredient
| NCT ID | Title | Status | Phase | Conditions | Start Date | Completion Date |
|---|
Manufacturing Locations
Unlock access to all suppliers of Halobetasol Propionate; Tazarotene
Note: Patent expirations and exclusivity timelines are dynamic and may shift based on litigation, regulatory extensions, and maintenance filings. Regular monitoring is advised.